Physician profile
Sandy Kraft
NPI 1346538386
$891.16
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $324 · 2020: $111 · 2021: $195 · 2022: $245 · 2023: $17.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $187.48 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $112.13 | 2020-2022 | |
| Johnson & Johnson Vision Care, INC. | $97.41 | 2019 | |
| Biotissue Holdings INC. | $90.88 | 2022 | |
| Ivantis, INC | $86.08 | 2019-2021 | |
| Carl Zeiss Meditec, INC. | $51.72 | 2019 | |
| Coopervision INC. | $49.95 | 2019-2022 | |
| Abbvie INC. | $44.95 | 2022 | |
| Alcon Vision LLC | $36.88 | 2021 | |
| Novartis Pharmaceuticals Corporation | $32.79 | 2021-2022 | |
| Oyster Point Pharma, INC. | $30.83 | 2022 | |
| Horizon Therapeutics Plc | $19.77 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $17.95 | 2021 | |
| Averitas Pharma INC. | $17.08 | 2023 | Qutenza |
| Bausch & Lomb Americas INC. | $15.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandy Kraft listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.